Federal Register / Vol. 60, No. 90 / Wednesday, May 10, 1995 / Notices 24871

Agenda: Dicussion of Institute extramural

research programs, health services research,

and other program and peer review issues

relevant to Council activities.

Closed: June 1, 8 a.m. to 10:30 a.m.

Agenda: To review and evaluate grant

applications.

The following review committee meetings

will be totally closed.

Name of Committee: Neuroscience and

Behavior Subcommittee of the Alcohol

Biomedical Research Review Committee.

Dates of Meeting: June 5–7, 1995.

Time: 9 a.m. to adjournment.

Place of Meeting: Hyatt Regency Bethesda,

One Bethesda Metro Center, Bethesda, MD

20814.

Contact Person: Antonio Noronha, Ph.D.,

Scientific Review Administrator, 6000

Executive Blvd, Suite 409, Bethesda, MD

20892–7003, 301–443–9419.

Agenda: To review and evaluate grant

applications.

Name of Committee: Clinical and

Treatment Subcommittee of the Alcohol

Psychosocial Research Review Committee.

Dates of Meeting: June 8–9, 1995.

Time: 8:30 a.m. to adjournment.

Place of Meeting: Hyatt Regency Bethesda,

One Bethesda Metro Center, Bethesda, MD

20814.

Contact Person: Elsie D. Taylor, Scientific

Review Administrator, 6000 Executive Blvd,

Suite 409, Bethesda, MD 20892–7003, 301–

443–9787.

Agenda: To review and evaluate grant

applications.

Name of Committee: Epidemiology and

Prevention Subcommittee of the Alcohol

Psychosocial Research Review Committee.

Dates of Meeting: June 8–9, 1995.

Time: 8:30 a.m. to adjournment.

Place of Meeting: Holiday Inn, 480 King

Street, Alexandra, VA.

Contact Person: Thomas D. Sevy, M.S.W.,

Scientific Review Administrator, 6000

Executive Blvd, Suite 409, Bethesda, MD

20892–7003, 301–443–6106.

Agenda: To review and evaluate grant

applications.

Name of Committee: Biochemistry,

Physiology, and Medicine Subcommittee of

the Alcohol Biomedical Research Review

Committee.

Dates of Meeting: June 15–17, 1995.

Place of Meeting: Double Tree Hotel,

Denver, CO.

Time: 9 a.m. to adjournment.

Contact Person: Ronald Suddendorf, Ph.D.,

Scientific Review Administrator, 6000

Executive Blvd, Suite 409, Bethesda, MD

20892–7003, 301–443–2932.

Agenda: To review and evaluate grant

applications.

(Catalog of Federal Domestic Assistance

Program No. 93.271, Alcohol Research Career

Development Awards for Scientists and

Clinicians; 93.272, Alcohol National

Research Service Awards for Research

Training; 93.273, Alcohol Research Programs;

93.281, Scientist Development Award,

Research Scientist Development Award,

Scientist Development Award for Clinicians,

and Research Scientist Award; 93.891,

Alcohol Research Center Grants; National

Institutes of Health).

Dated: May 3, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–11421 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Arthritis and

Musculoskeletal and Skin Disease;

Notice of Meeting of the National

Arthritis and Musculoskeletal and Skin

Diseases Advisory Council

Pursuant to Public Law 92–463,

notice is hereby given of a meeting of

the National Arthritis and

Musculoskeletal and Skin Diseases

Advisory Council to provide advice to

the National Institute of Arthritis and

Musculoskeletal and Skin Diseases on

June 1 and 2, 1995, Conference Room 6,

Building 31, National Institutes of

Health, Bethesda, Maryland.

The meeting will be open to the

public June 1 from 8:30 a.m. to 9 a.m.

to discuss administrative details relating

to Council business and special reports.

Attendance by the public will be limited

to space available.

The meeting of the Advisory Council

will be closed to the public on June 1

from 9 a.m. to approximately 5 p.m. and

if necessary the closed portion will

continue on June 2 from 8:30 a.m. to

adjournment in accordance with

provisions set forth in secs. 552b(c)(4)

and 552b(c)(6), Title 5, U.S.C. and

section 10(d) of Public Law 92–463, for

the review, discussion and evaluation of

individual grant applications. These

deliberations could reveal confidential

trade secrets or commercial property,

such as patentable materials, and

personal information concerning

individuals associated with the

applications, disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

Individuals who plan to attend and

need special assistance, such a sign

language interpretation or other

reasonable accommodations, should

contact Dr. Tommy Broadwater,

Executive Secretary, National Arthritis

and Musculoskeletal and Skin Diseases

Advisory Council, NIAMS, Natcher

Building, Room 5AS–13, Bethesda,

Maryland 20892, (301) 594–2463.

A summary of the meeting and roster

of the members may be obtained from

the Extramural Programs Office,

NIAMS, Natcher Bldg., Rm. 5AS–13,

National Institutes of Health, Bethesda,

Maryland 20892, (301) 594–2463.

(Catalog of Federal Domestic Assistance

Program No. 93.846, Arthritis, Bone and Skin

Diseases, National Institutes of Health)

Dated: May 3, 1995.

Susan K. Feldman,

NIH Committee Management Officer.

[FR Doc. 95–11419 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institute; Notice of Meeting

Notice is hereby given of the meeting

of the National Heart Attack Alert

Program Coordinating Committee,

sponsored by the National Heart, Lung,

and Blood Institute on June 13, 1995,

from 8:30 a.m. to 3:15 p.m., at the

Bethesda Holiday Inn Hotel, 8120

Wisconsin Avenue, Bethesda, Maryland

20814, (301) 652–2000.

The entire meeting is open to the

public. The Coordinating Committee is

meeting to discuss the progress of the

National Heart Attack Alert Program

with its participating organizations.

Attendance by the public will be limited

to space available.

For the detailed program information,

agenda, list of participants, and meeting

summary, contact: Ms. Mary McDonald

Hand, Coordinator, National Heart

Attack Alert Program, Office of

Prevention, Education and Control,

National Heart, Lung, and Blood

Institute, National Institutes of Health,

31 Center Drive MSC 2480, Bethesda,

Maryland 20892–2480, (301) 496–1051.

Dated: May 3, 1995.

Claude Lenfant,

Director, NHLBI.

[FR Doc. 95–11425 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–P

National Institute of Mental Health;

Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings of the National Institute of

Mental Health Special Emphasis Panel:

Agenda/Purpose

To review and evaluate grant applications.

Committee Name: National Institute of

Mental Health Special Emphasis Panel.

Date: June 5, 1995.

Time: 2 p.m.

Place: Parklawn Building, Room 9C–26,

5600 Fishers Lane, Rockville, MD 20857.

Contact Person: Phyllis D. Artis, Grant

Technical Assistant, Parklawn Building,

Room 9C–26, 5600 Fishers Lane, Rockville,

MD 20857, Telephone: 301, 443–6470.

Committee Name: National Institute of

Mental Health Special Emphasis Panel.

Date: June 6, 1995.

Time: 12:30 p.m.

Place: Parklawn Building, Room 9C–26,

5600 Fishers Lane, Rockville, MD 20857.
24872 Federal Register / Vol. 60, No. 90 / Wednesday, May 10, 1995 / Notices

Contact Person: Phyllis D. Artis, Grant

Technical Assistant, Parklawn Building,

Room 9C–26, 5600 Fishers Lane, Rockville,

MD 20857, Telephone: 301, 443–6470.

The meetings will be closed in

accordance with the provisions set forth

in sec. 552b(c)(4) and 552b(c)(6), Title 5,

U.S.C. Applications and/or proposals

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals associated with the

applications and/or proposals, the

disclosure of which would constitute

clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers 93.126, Small Business

Innovation Research; 93.176, ADAMHA

Small Instrumentation Program Grants;

93.242, Mental Health Research Grants;

93.281, Mental Research Scientist

Development Award and Research Scientist

Development Award for Clinicians; 93.282,

Mental Health Research Service Awards for

Research Training; and 93.921, ADAMHA

Science Education Partnership Award.)

Dated: May 3, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–11420 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive

License: Oncoimmunins

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(I) that the National Institutes

of Health and Human Services, is

contemplating the grant of an exclusive

world-wide license to practice the

inventions embodied in a U.S. Patent

5,364,619 and U.S. Patent Applications;

USSN 07/764,695 and USSN 08/218,023

and corresponding foreign patent

applications each entitled,

‘‘Oncoimmunins’’ to OncoImmunin,

Inc. of Kensington, Maryland. The

patent rights in these inventions have

been assigned to the United States of

America.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless

within sixty (60) days from the date of

this published notice, NIH receives

written evidence and argument that

establishes that the grant of the license

would not be consistent with the

requirements of 35 U.S.C. 209 and 37

CFR 404.7.

Tumor-infiltrating lymphocytes (TILs)

have shown in vivo antitumor efficacy

in both animal and human studies.

Functions thought necessary for

antitumor activity include cytolysis,

homing, and proliferation at tumor sites.

T-cell mitogens of tumor origin have

been suggested to be responsible, in

part, for the local stimulation of Tlymphocytes around tumors. Two

tumor-derived, soluble proteins named

Oncoimmunin-L and Oncoimmunin-M

have been isolated and partially

characterized. Oncoimmunin-L is a Tcell mitogen and Oncoimmunin-M is a

myeloid differentiation inducing agent.

The partial characterization of these two

factors has shown that they are similar

to human leukocyte elastase inhibitor

and human lactate dehydrogenase M,

respectively. As cells of both lymphoid

and myeloid origin are known to play

roles in immune defense, factors which

can modulate their number and/or

function may be useful in the diagnosis

and treatment of cancer. Since these

factors are derived from tumors, their

appearance in blood may signal the

presence of tumor or of metastatic

disease. The in vivo bioactivities of

these factors suggests their utility as

therapeutic agents for cancer and

infectious diseases.

ADDRESSES: Requests for copies of the

patent applications, inquiries,

comments and other materials relating

to the contemplated licenses should be

directed to: Raphe Kantor, Ph.D.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804. Telephone: (301)

496–7735 ext. 247; Facsimile: (301)

402–0220. A signed Confidentiality

Agreement will be required to receive

copies of the patent applications.

Applications for a license in any field of

use filed in response to this notice will

be treated as objections to the grant of

the contemplated licenses. Only written

comments and/or applications for a

license which are received by NIH on or

before July 10, 1995 will be considered.

Dated: April 24, 1995.

Maria C. Freire,

Director, Office of Technology Transfer.

[FR Doc. 95–11423 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–P

Prospective Grant of Exclusive

License: Neuro-Derived Fetal Cell

Lines for Transplantation Therapy

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of an exclusive world-wide

license to practice the inventions

embodied in U.S. Patent 4,707,448,

entitled ‘‘Immortal Line of Human Fetal

Glial Cells,’’ U.S. Patent Application SN

08/046,527 entitled ‘‘Use of NeuroDerived Fetal Cell Line for

Transplantation Therapy’’ and

corresponding foreign patent

applications to Pro-Virus, Inc. of

Rockville, Maryland. The patent rights

in these inventions have been assigned

to the United States of America.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless

within 60 days from the date of this

published notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

The patent discloses a novel

immortalized fetal glial cell line,

designated SVG. The pending patent

application discloses the methods of

using such cell lines or genetically

modified clones thereof for therapeutic

purposes to treat various neurological

diseases and disorders via

transplantation of the cell lines into the

patient. Cell lines, such as SVG, have

the advantage of being a continually

renewable resource and relatively

homogenous. Additionally, such cell

lines eliminate the significant safety

concerns associated with primary

human fetal tissue transplants that may

harbor opportunistic disease-causing

agents and may be subjected to a battery

of tests to ensure their safety and

efficacy before being used in

transplantation.

ADDRESSES: Requests for copies of the

patent and the patent applications,

inquiries, comments and other materials

relating to the contemplated licenses

should be directed to: Mr. Arthur J.

Cohn, Esq., Technology Licensing

Specialist, Office of Technology

Transfer, National Institutes of Health,

6011 Executive Boulevard, Suite 325,

Rockville, Maryland 20892–3804.

Telephone: (301) 496–7735 ext 284;

Facsimile: (301) 402–0220. A signed

Confidentiality Agreement will be

required to receive copies of the patent

applications. Applications for a license

in the field of use filed in response to

this notice will be treated as objections

to the grant of the contemplated